Immune Related Adverse Events (iraes) - Cancer Science

Relevant Publications

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort.

Issue Release: 2024

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.

Issue Release: 2024

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.

Issue Release: 2024

Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.

Issue Release: 2024

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Issue Release: 2024

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update.

Issue Release: 2024

Multidisciplinary management of immunotherapy-related adverse events in solid tumors: An inter-institutional and telemedicine-based working team.

Issue Release: 2024

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.

Issue Release: 2024

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Issue Release: 2024

Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma.

Issue Release: 2024

Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study.

Issue Release: 2024

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.

Issue Release: 2024

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer.

Issue Release: 2024

An updated patent review on PD-1/PD-L1 antagonists (2022-present).

Issue Release: 2024

Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review.

Issue Release: 2024

Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study.

Issue Release: 2024

Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report.

Issue Release: 2024

Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.

Issue Release: 2024

Immune checkpoint inhibitor-associated gastritis: Patterns and management.

Issue Release: 2024

Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics